Cite
HARVARD Citation
Nakamura, M. et al. (n.d.). 2096 Phase II trial of Irinotecan plus S-1 (IRIS) with Cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type of metastatic colorectal cancer (mCRC): HGCSG0902 updated analysis. European journal of cancer. pp. S360-. [Online].